A selective NaV1.1 activator with potential for treatment of Dravet syndrome epilepsy.

A selective NaV1.1 activator with potential for treatment of Dravet syndrome epilepsy.

  • Post by:
  • 7 July 2020
  • Comments off
Categories:

Major funding support

Participating Institutions

The University of Queensland
The University of Sydney
Australian National University
Monash University
Queensland University of Technology
Edith Cowan University
CSIRO

International Partners

Boston Children’s Hospital, Harvard
University of Washington
University of Tokyo
Massachusetts Institute of Technology
University of Illinois at Urbana-Champaign
University of Southampton

Latest Events

Twitter
YouTube

Publications Statistics

22 leading Scientists

CIPPS brings together the expertise of 22 world-leading peptide and protein scientists.

1800 Publications

Cumulatively, CIPPS researchers have published over 1800 publications, books and book chapters in the past 10 years.

310,000 Citations

CIPPS researchers have been cited over 310,000 times.